GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Verona Pharma PLC (NAS:VRNA) » Definitions » Other Stockholders Equity

VRNA (Verona Pharma) Other Stockholders Equity : $0.00 Mil (As of Dec. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Verona Pharma Other Stockholders Equity?

Verona Pharma's Other Stockholders Equity for the quarter that ended in Dec. 2024 was $0.00 Mil.

Verona Pharma's quarterly Other Stockholders Equity increased from Jun. 2024 ($-0.00 Mil) to Sep. 2024 ($0.00 Mil) but then declined from Sep. 2024 ($0.00 Mil) to Dec. 2024 ($0.00 Mil).

Verona Pharma's annual Other Stockholders Equity stayed the same from Dec. 2022 ($0.00 Mil) to Dec. 2023 ($0.00 Mil) and stayed the same from Dec. 2023 ($0.00 Mil) to Dec. 2024 ($0.00 Mil).


Verona Pharma Other Stockholders Equity Historical Data

The historical data trend for Verona Pharma's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Verona Pharma Other Stockholders Equity Chart

Verona Pharma Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Other Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Verona Pharma Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Verona Pharma Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity


Verona Pharma Other Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Verona Pharma's Other Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Verona Pharma Business Description

Traded in Other Exchanges
Address
3 More London Riverside, London, GBR, SE1 2RE
Verona Pharma PLC is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. The company is currently focusing on developing its Ensifentrine product candidate, which will treat chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and other respiratory diseases, including asthma.
Executives
Kathleen A. Rickard officer: Chief Medical Officer C/O VERONA PHARMA PLC, 3 MORE LONDON RIVERSIDE, LONDON X0 SE1 2RE
Mark W Hahn officer: Chief Financial Officer 6340 QUADRANGLE DRIVE, SUITE 100, CHAPEL HILL NC 27517
David Zaccardelli director, officer: President and CEO 300 TRI STATE INTERNATIONAL, SUITE 272, LINCOLNSHIRE IL 60069
David R Ebsworth director C/O CURAGEN CORP, 555 LONG WHARF DR. 11TH FL., NEW HAVEN CT 06511
Christina Ackermann director C/O BLCO, 400 SOMERSET CORPORATE BLVD., BRIDGEWATER NJ 08807
Martin Edwards director 15 NEW ENGLAND EXECUTIVE PARK, BURLINGTON MA 01803
Claire Poll officer: General Counsel C/O VERONA PHARMA PLC, 3 MORE LONDON RIVERSIDE, LONDON X0 SE1 2RE
Orbimed Advisors Llc director, 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Rishi Gupta director, 10 percent owner C/O CHEMOCENTRYX, INC., 850 MAUDE AVENUE, MOUNTAIN VIEW CA 94043
Access Industries Holdings Llc 10 percent owner C/O ACCESS INDUSTRIES MANAGEMENT, LLC., 730 FIFTH AVENUE, 20TH FLOOR, NEW YORK NY 10019
Ai Biotechnology Llc 10 percent owner C/O ACCESS INDUSTRIES, INC., 40 WEST 57TH STREET, 28TH FLOOR, NEW YORK NY 10019
Access Industries Management, Llc 10 percent owner 730 FIFTH AVENUE, NEW YORK NY 10019
Len Blavatnik 10 percent owner C/O ACCESS INDUSTRIES, 730 FIFTH AVENUE, NEW YORK NY 10019
James Aloysius Brady director C/O VERONA PHARMA PLC, 3 MORE LONDON RIVERSIDE, LONDON X0 SE1 2RE
Lisa Deschamps director C/O VERONA PHARMA PLC, 3 MORE LONDON RIVERSIDE, LONDON X0 SE1 2RE